Business
Citius Pharmaceuticals Announces Publication in Antimicrobial Agents and Chemotherapy Journal of Positive Preclinical Results for Mino-Lok® in Rapidly Eradicating Candida Auris
March 2020 issue of AAC journal highlights in vitro study at MD Anderson Cancer Center Labs that shows Mino-Lok to be effective in completely eradicating all
About this update from Citius Pharmaceuticals, Inc.
[{"type":"text","content":"March 2020 issue of AAC journal highlights in vitro study at MD Anderson Cancer Center Labs that shows Mino-Lok to be effective in completely eradicating all ten strains of Candida auris tested\n\n\nCRANFORD, N.J., March 26, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. (\"Citius\" or the \"Company\") (Nasdaq: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced today the publication of an in vitro study for Mino-Lok®, the Company's antibiotic lock solution used to treat patients with central line associated blood stream infections (CLABSIs) and catheter-related bloodstream infections (CRBSIs), in the March 2020 issue of Antimicrobial Agents and Chemotherapy. The article, titled \"Minocycline-EDTA-Ethanol Antimicrobial Catheter Lock Solution Is Highly Effective In Vitro for Eradication of Candida auris Biofilms,\" highlights the in vitro efficacy of Mino-Lok against various strains of Candida auris (\"C. auris\") from studies conducted at MD Anderson Cancer Center Labs. \nMr. Myron Holubiak, Chief Executive Officer of Citius, said, \"We're happy to have the positive preclinical results of Mino-Lok published in the AAC Journal. Candida auris is a very problematic type of fungus, but the results from these in vitro studies showed that complete eradication of all strains of C. auris occurred within an hour of exposure to Mino-Lok. We anticipate completing our Phase 3 trial with Mino-Lok by the end of 2020, which will bring us one step closer to treating patients with infected catheters from any number of fungi or bacteria.\" \nC. auris is a fungus that can cause serious bloodstream infections or death, particularly in hospital and nursing home patients with serious medical problems. More than one in three patients with invasive C. auris infection die. The fungus is often resistant to most antifungal agents commonly used to treat Candida infections. Although C. auris was just recently discovered in 2009, it has spread quickly and caused infections in more than a dozen countries. Patients who have been hospitalized in a healthcare facility a long time, have a central venous catheter or other lines or tubes entering their body, or have previously received antibiotics or antifungal medications, appear to be at highest risk of infection with this yeast. \nAbout Mino-L...